Literature DB >> 1677807

Population dynamics of HIV within an individual after treatment with zidovudine.

A R McLean1, V C Emery, A Webster, P D Griffiths.   

Abstract

A new mechanism is proposed for the apparent breakthrough of HIV that occurs approximately 6 months after the commencement of therapy with zidovudine (AZT). Using a simple mathematical model of the interacting population dynamics of HIV and its major host cell in the circulation (the CD4+ lymphocyte), predicted patterns of HIV plasma viraemia in the weeks following treatment with zidovudine are generated. These are in close agreement with observed patterns despite the fact that the model contains no mechanisms for the development of drug-resistant strains of virus. It is suggested that the patterns of viral abundance observed during the first 6 months after treatment may be the result of non-linearities in the interactions between HIV and CD4+ cells, and that it is only after the first post-treatment burst of viral production that drug resistance plays an important role.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1677807     DOI: 10.1097/00002030-199105000-00002

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  13 in total

1.  HIV therapy: managing resistance.

Authors:  D Wodarz; M A Nowak
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-18       Impact factor: 11.205

2.  Production of resistant HIV mutants during antiretroviral therapy.

Authors:  R M Ribeiro; S Bonhoeffer
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

3.  Understanding the failure of CD8+ T-cell vaccination against simian/human immunodeficiency virus.

Authors:  Rob J De Boer
Journal:  J Virol       Date:  2007-01-03       Impact factor: 5.103

4.  Virus dynamics and drug therapy.

Authors:  S Bonhoeffer; R M May; G M Shaw; M A Nowak
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-24       Impact factor: 11.205

5.  Short-term measures of relative efficacy predict longer-term reductions in human immunodeficiency virus type 1 RNA levels following nelfinavir monotherapy.

Authors:  J Mittler; P Essunger; G J Yuen; N Clendeninn; M Markowitz; A S Perelson
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

6.  Viral dynamics of acute HIV-1 infection.

Authors:  S J Little; A R McLean; C A Spina; D D Richman; D V Havlir
Journal:  J Exp Med       Date:  1999-09-20       Impact factor: 14.307

7.  Small variations in multiple parameters account for wide variations in HIV-1 set-points: a novel modelling approach.

Authors:  V Müller; A F Marée; R J De Boer
Journal:  Proc Biol Sci       Date:  2001-02-07       Impact factor: 5.349

8.  Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine.

Authors:  M D de Jong; J Veenstra; N I Stilianakis; R Schuurman; J M Lange; R J de Boer; C A Boucher
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-28       Impact factor: 11.205

9.  A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants.

Authors:  Bambang S Adiwijaya; Eva Herrmann; Brian Hare; Tara Kieffer; Chao Lin; Ann D Kwong; Varun Garg; John C R Randle; Christoph Sarrazin; Stefan Zeuzem; Paul R Caron
Journal:  PLoS Comput Biol       Date:  2010-04-15       Impact factor: 4.475

10.  A pharmacokinetic-pharmacodynamic model of chemotherapy of human immunodeficiency virus infection that relates development of drug resistance to treatment intensity.

Authors:  R C Jackson
Journal:  J Pharmacokinet Biopharm       Date:  1997-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.